017180 — Myungmoon Pharm Co Balance Sheet
0.000.00%
- KR₩57bn
- KR₩149bn
- KR₩186bn
Annual balance sheet for Myungmoon Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Interim Report | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 7,318 | 7,097 | 5,264 | 8,064 | 4,558 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 35,659 | 30,345 | 34,700 | 38,928 | 42,190 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 80,577 | 67,466 | 70,707 | 81,436 | 80,329 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 149,944 | 142,861 | 141,777 | 140,196 | 161,994 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 243,025 | 223,263 | 230,450 | 236,549 | 257,988 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 125,320 | 113,088 | 110,821 | 116,373 | 92,660 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 155,824 | 143,006 | 140,928 | 153,096 | 161,137 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 87,201 | 80,257 | 89,522 | 83,453 | 96,851 |
Total Liabilities & Shareholders' Equity | 243,025 | 223,263 | 230,450 | 236,549 | 257,988 |
Total Common Shares Outstanding |